Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00203463

Enrollment

Registered

2005-09-20

Start date

2001-07-31

Completion date

2004-09-30

Last updated

2009-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Keywords

topiramate, PTSD, posttraumatic stress disorder, topamax

Brief summary

To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Detailed description

This is a twelve-week randomized, double blind, placebo controlled trial of topiramate for 40 patients with PTSD. Diagnoses are made by Structured Clinical Interview for DSM-IV (SCID). Symptom severity is measured with the Clinician Administered PTSD Scale (CAPS), Davidson Trauma Scale (DTS), Treatment Outcome PTSD (TOP-8), Clinical Global Impressions (CGI), and the Hamilton Rating Scales for Depression and Anxiety (HAM-D and HAM-A). The Clinician Administered PTSD Scale (CAPS) is the primary outcome measure. Subjects will read and sign informed consent prior to beginning any study procedures. Subjects who meet inclusion/exclusion criteria will be randomized 1:1 (Topiramate : placebo) to study medication. Study medication is initiated at one tablet daily (25mg topiramate or placebo) and medication will be increased by 25-100mg (1 tablet) increments every 7 days, as tolerated, until a maximum benefit is achieved, not to exceed 400mg/day. Patients will be seen every week up until Visit 4, and then will be seen every two weeks for the remainder of the study for assessment of efficacy and side effects.

Interventions

DRUGtopiramate

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of PTSD DSM-IV criteria * No substance abuse/dependence for the previous 2 months (except for nicotine and caffeine) * Free of psychotropic medication, for 2 weeks (except 6 weeks for fluoxetine) * Normal physical and laboratory examination (lab profile listed below) * Negative urine screen for drugs of abuse * Women of childbearing potential must be using nonpharmacologic medically approved methods of birth control * Signed informed consent * Male or female, any race or ethic origin

Exclusion criteria

* Lifetime history of bipolar, psychotic, or cognitive disorders * Suicidal, homicidal, or psychotic * Diagnosis of bulimia or anorexia nervosa * History of sensitivity to topiramate * General medical conditions or ongoing treatment that contraindicate the use of topiramate, such as seizure disorder or use of MAO inhibitors. * Women planning to become pregnant or breastfeed during the study

Design outcomes

Primary

Measure	Time frame
Potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD as noted in the change of the 17-item total severity score of the Clinician-Administered PTSD scale (CAPS) from baseline to the last visit of Double-Blind Phase (8-weeks)	(8-weeks)

Secondary

Measure	Time frame
Changes from baseline to the last visit in Double-Blind Phase for HAM-A, MADRS, and TOP-8 Scale, Clinical Global Impression (CGI)scales, and Davidson Trauma Scale (DTS). Each scale will be analyzed as described above for the primary efficacy variable.	(8-weeks)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026